the early use of antibiotics in at risk children with influenza twitter: @archiestudy chief...

21
The early use of Antibiotics in at Risk CHildren with InfluEnza www.archiestudy.com Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial Manager: Tricia Carver

Upload: quentin-owens

Post on 25-Dec-2015

214 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

The early use of Antibiotics in at Risk CHildren with InfluEnza

www.archiestudy.comTwitter: @archiestudy

Chief Investigator: Dr Kay WangSenior Trial Manager: Tricia Carver

Page 2: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Research questions

• Does early antibiotic use in ‘at risk’ children with influenza-like illness reduce the likelihood of re-consultation due to clinical deterioration?

• What impact might early antibiotic use have on antimicrobial resistance?

• Is early antibiotic use cost effective?

Page 3: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Recruitment plan

• 650 ‘at risk’ children with influenza-like illness

• Winters 2014/5 and 2015/6 (+/- 2016/7)– October to March – Bulk of recruitment during peak influenza season

(December/January)

• Target: 8 recruits per site per season (2 per month)

Page 4: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Patients to consider for ARCHIE

• ‘At risk’ children aged 6 months to 12 years

• Cough AND fever (fever reported as symptom or temperature 37.9°C or higher during consultation)

• Within 5 days of symptom onset

• No known contraindication to co-amoxiclav

• Does not require immediate antibiotics or hospitalisation

Page 5: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Archie is more ill than usual when he just gets a cold or flu………

………………but I’m not sure if he is ill enough to need antibiotics.

Page 6: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Summary of study

Day 1 Day 28Day 7 Day 14

Enrolment and randomisation

Day 21 3m +

Page 7: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Summary of study

Day 1 Day 28Day 7 Day 14

Enrolment and randomisation

Day 21 3m +

Page 8: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Summary of study

Day 1 Day 28Day 7 Day 14

Return weekly diaries (parent ± child)

Enrolment and randomisation

Day 21 3m +

Page 9: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Summary of study

Medical notes review (study team)

Day 1 Day 28Day 7 Day 14

Return weekly diaries (parent ± child)

Enrolment and randomisation

Day 21 3m +

Page 10: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Recruitment timeframe

• Same day if possible

• Following (working) day if still meet eligibility criteria– Complete eligibility assessment form on the same

day as the baseline appointment

Page 11: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Study enrolment (face to face)• Full eligibility assessment• Baseline assessment

• Introduce the study • Initial eligibility assessment (healthcare professionals)• Eligibility criteria and information leaflets available

from www.archiestudy.com

Triage nurse ClinicianReceptionist

Page 12: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Recruitment tip 1• Ask parents and children to read the study

information leaflets before the baseline appointment

• Patients can go to www.archiestudy.com to:– Watch video clips about the study– Download study information leaflets– Read our Frequently Asked Questions

Page 13: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Baseline appointment (day 1)

• To be completed by healthcare professional– Eligibility assessment – Consent +/- assent– Baseline clinical assessment– Randomise and allocate study medication– Contact card

• To be completed by parent/guardian ± child– Contact information form– Questionnaires (two for parent, one for child)– Study diaries

Page 14: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Recruitment tip 2

• Use the armpit thermometer provided to take the child’s temperature, and show the parent how to use it at the same time

Page 15: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Recruitment tip 3• While you prepare the child’s study

medication, ask the parent and child to:– Complete the contact information form– Complete the study questionnaires– Look through the Diary – Instructions and

Overview

Page 16: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Study medication • Co-amoxiclav 400/57 or matching placebo• Randomisation system accessible via website• Key instructions for parents:– Keep medication refrigerated once reconstituted– Give first dose as soon as possible (consider during

baseline appointment)– Can repeat dose if child vomits within 30 minutes

of dose– Give child maximum of 10 doses– Discard leftover medication

Page 17: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Follow-up assessments

• Telephone follow-ups– Week 1 (day 7 to 10)– Week 2 (day 14 to 17)

• Objectives– Safety monitoring– Reminders to complete and return diaries

• No need to ask consent for follow-up throat swabs for children who have not been recruited from a GP surgery

Page 18: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Reimbursement

• Service support costs – Insert region specific details

• Research costs– Reimbursed annually by study team– £16.48 per child recruited into trial

Page 19: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

Thank you for listening

E-mail: [email protected]: 01865 617842

Funded by NIHR Programme Grant for Applied Research RP-PG-1210-12012

Page 20: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

FAQ- online systems Online service

Use How to access (live systems*)

Website Training, reference documents, and access to the other online systems.

Log in by clicking on link in top right hand corner of front page. Additional links will appear under the ‘Randomise your patient’ section.

Sortition Randomisation system which generates study medication ID to be allocated to participant

Directly from website (Web Randomisation link) or from link in baseline assessment form* (randomisation page opens in a separate tab on the browser).

OpenClinica Clinical database for entering CRF data

Under ‘Randomise your patient’ there are links to ‘Eligibility Form’ and ‘Follow-up data collection’*. A link to the baseline assessment form* will appear once you have completed the eligibility form.

Page 21: The early use of Antibiotics in at Risk CHildren with InfluEnza  Twitter: @archiestudy Chief Investigator: Dr Kay Wang Senior Trial

FAQ- reconsultationQ: What is the procedure if a child reconsults because they are unwell while they are still taking their study medication?

A: The clinician should assess and manage the child as they would based on their usual clinical practice. This may include issuing a prescription for antibiotics if the clinician considers that antibiotic treatment is indicated. The BNF states that the standard dose of co-amoxiclav can be doubled* when treating severe infections. The study medication dosing regimen in ARCHIE is based on the BNF standard dosing regimen. The child can therefore continue taking their study medication unless there is a reason to stop it (e.g. suspected allergic reaction).*caution advised in children with underlying conditions which may compromise the excretion or metabolism of co-amoxiclav, and in children weighting less than 6kg. In these children, an alternative antibiotic should be considered.